View Section: Financials
NewAmsterdam Pharma Statements
NA
NewAmsterdam Pharma Income Statement
B
M
USD (except Earnings per share)
Financial
Revenue
Cost of sales
Gross profit
Research and development
Selling, general and administrative
Total operating expenses
Operating income
Interest expense
Other income
Income before tax
Provision for income taxes
Net income
Diluted earnings per share
Shares outstanding after dilution
2022-12-31
%
97.5
100
—
0
—
0
82.23
84.3
13.928
14.3
101.44
104
-3.939
-4.04
-10.492
-10.8
—
0
-78.052
-80.05
—
0
-78.052
-80.05
-0.955
81.768
2022-09-30
%
—
100
—
0
—
0
—
0
2.294
0
2.294
0
-2.294
0
-2.487
0
—
0
-4.78
0
—
0
-4.78
0
-0.269
17.751
2022-06-30
%
—
100
—
0
—
0
30.588
0
1.991
0
1.991
0
-1.991
0
0.818
0
—
0
-1.173
0
—
0
-1.173
0
-0.066
17.751
2022-03-31
%
—
100
—
0
—
0
—
0
0.345
0
0.345
0
-0.345
0
1.729
0
—
0
1.385
0
—
0
1.385
0
0.078
17.751
2021-12-31
%
—
100
—
0
—
0
25.032
0
0.455
0
0.455
0
-0.455
0
0.384
0
1
0
0.93
0
—
0
0.93
0
0.052
17.751
2021-09-30
%
—
100
—
0
—
0
—
0
0.369
0
0.369
0
-0.369
0
2.099
0
—
0
1.73
0
—
0
1.73
0
0.097
17.751
View Section: Balance Sheet